Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Meza-Zepeda LA"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 51
Tytuł:
Heritable defects in telomere and mitotic function selectively predispose to sarcomas.
Autorzy:
Ballinger ML; Garvan Institute of Medical Research, Sydney 2010, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney 2010, Australia.
Pattnaik S; Garvan Institute of Medical Research, Sydney 2010, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney 2010, Australia.
Mundra PA; Garvan Institute of Medical Research, Sydney 2010, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney 2010, Australia.
Zaheed M; Hereditary Cancer Centre, Prince of Wales Hospital, Sydney 2031, Australia.
Rath E; Garvan Institute of Medical Research, Sydney 2010, Australia.
Priestley P; Hartwig Medical Foundation, 1098 XH Amsterdam, Netherlands.; Hartwig Medical Foundation Australia, Sydney 2000, Australia.
Baber J; Hartwig Medical Foundation, 1098 XH Amsterdam, Netherlands.; Hartwig Medical Foundation Australia, Sydney 2000, Australia.
Ray-Coquard I; Department of Adult Medical Oncology, Centre Leon Berard, University Claude Bernard, 69373 Lyon, France.
Isambert N; Centre Georges Francois Leclerc, 21000 Dijon, France.
Causeret S; Centre Georges Francois Leclerc, 21000 Dijon, France.
van der Graaf WTA; Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Puri A; Department of Orthopedic Oncology, Tata Memorial Hospital, Mumbai, Maharashtra 400012, India.
Duffaud F; la Timone University Hospital, 13005 Marseille, France.
Le Cesne A; Gustave Roussy, 94805 Villejuif, France.
Seddon B; Sarcoma Unit, University College Hospital, London NW1 2BU, UK.
Chandrasekar C; Liverpool University Hospitals NHS Foundation Trust, Liverpool L7 8XP, UK.
Schiffman JD; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Brohl AS; Sarcoma Department, Moffitt Cancer Center, Tampa, FL 33612, USA.
James PA; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne 3010, Australia.; Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne 3000, Australia.
Kurtz JE; Centre Hospitalier Universitaire Hautepierre, 67200 Strasbourg, France.
Penel N; Centre Oscar Lambret, 59000 Lille, France.
Myklebost O; Western Norway Familial Cancer Centre, Haukeland University Hospital, 5021 Bergen, Norway.; Department of Clinical Science, University of Bergen, 5007 Bergen, Norway.; Institute for Cancer Research, Oslo University Hospital, N-0424 Oslo, Norway.
Meza-Zepeda LA; Institute for Cancer Research, Oslo University Hospital, N-0424 Oslo, Norway.
Pickett H; Children's Medical Research Institute, The University of Sydney, Westmead 2145, Australia.
Kansara M; Garvan Institute of Medical Research, Sydney 2010, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney 2010, Australia.
Waddell N; QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia.
Kondrashova O; QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia.
Pearson JV; QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia.
Barbour AP; Faculty of Medicine. The University of Queensland, Brisbane 4072, Australia.
Li S; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne 3010, Australia.; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton 3800, Australia.; Murdoch Children's Research Institute, Royal Children's Hospital, Parkville 3051, Australia.
Nguyen TL; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne 3010, Australia.
Fatkin D; St Vincent's Clinical School, University of New South Wales, Sydney 2010, Australia.; Molecular Cardiology Division, Victor Chang Cardiac Research Institute, Darlinghurst 2010, Australia.; Cardiology Department, St Vincent's Hospital, Sydney 2010, Australia.
Graham RM; St Vincent's Clinical School, University of New South Wales, Sydney 2010, Australia.; Molecular Cardiology Division, Victor Chang Cardiac Research Institute, Darlinghurst 2010, Australia.
Giannoulatou E; St Vincent's Clinical School, University of New South Wales, Sydney 2010, Australia.; Computational Genomics Division, Victor Chang Cardiac Research Institute, Sydney 2010, Australia.
Green MJ; School of Psychiatry, University of New South Wales, Sydney 2052, Australia.; Neuorscience Research Australia, Sydney 2031, Australia.
Kaplan W; Garvan Institute of Medical Research, Sydney 2010, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney 2010, Australia.
Ravishankar S; Garvan Institute of Medical Research, Sydney 2010, Australia.
Copty J; Garvan Institute of Medical Research, Sydney 2010, Australia.
Powell JE; Garvan Institute of Medical Research, Sydney 2010, Australia.; UNSW Cellular Genomics Futures Institute, University of New South Wales, Sydney 2052, Australia.
Cuppen E; Hartwig Medical Foundation, 1098 XH Amsterdam, Netherlands.
van Eijk K; Department of Neurology, University Medical Centre Utrecht Brain Center, Utrecht University, 3584 CX Utrecht, Netherlands.
Veldink J; Department of Neurology, University Medical Centre Utrecht Brain Center, Utrecht University, 3584 CX Utrecht, Netherlands.
Ahn JH; Department of Oncology, Asan Medical Centre, Seoul 05505, South Korea.
Kim JE; Department of Oncology, Asan Medical Centre, Seoul 05505, South Korea.
Randall RL; Department of Orthopaedic Surgery, University of California, Davis Health, Sacramento, CA 95817, USA.
Tucker K; Hereditary Cancer Centre, Prince of Wales Hospital, Sydney 2031, Australia.
Judson I; Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Sarin R; Cancer Genetics Unit, ACTREC, Tata Memorial Centre, Mumbai, Maharashtra 410210, India.
Ludwig T; Université de Brest, Inserm, EFS, UMR 1078, GGB, CHU de Brest, 29200 Brest, France.
Genin E; Université de Brest, Inserm, EFS, UMR 1078, GGB, CHU de Brest, 29200 Brest, France.
Deleuze JF; Centre National de Recherche en Génomique Humaine, Institut de Génomique, 91057 Evry, France.
Haber M; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Kensington 2033, Australia.
Marshall G; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Kensington 2033, Australia.; Kids Cancer Centre, Sydney Children's Hospital, Randwick 2031, Australia.
Cairns MJ; School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan 2308, Australia.; Centre for Brain and Mental Health Research, The Hunter Medical Research Institute, Newcastle 2305, Australia.
Blay JY; Department of Adult Medical Oncology, Centre Leon Berard, University Claude Bernard, 69373 Lyon, France.
Thomas DM; Garvan Institute of Medical Research, Sydney 2010, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney 2010, Australia.
Tattersall M
Neuhaus S
Lewis C
Tucker K
Carey-Smith R
Wood D
Porceddu S
Dickinson I
Thorne H
James P
Ray-Coquard I
Blay JY
Cassier P
Le Cesne A
Duffaud F
Penel N
Isambert N
Kurtz JE
Puri A
Sarin R
Ahn JH
Kim JE
Ward I
Judson I
van der Graaf W
Seddon B
Chandrasekar C
Rickar R
Hennig I
Schiffman J
Randall RL
Silvestri A
Zaratzian A
Tayao M
Walwyn K
Niedermayr E
Mang D
Clark R
Thorpe T
MacDonald J
Riddell K
Mar J
Fennelly V
Wicht A
Zielony B
Galligan E
Glavich G
Stoeckert J
Williams L
Djandjgava L
Buettner I
Osinki C
Stephens S
Rogasik M
Bouclier L
Girodet M
Charreton A
Fayet Y
Crasto S
Sandupatla B
Yoon Y
Je N
Thompson L
Fowler T
Johnson B
Petrikova G
Hambridge T
Hutchins A
Bottero D
Scanlon D
Stokes-Denson J
Génin E
Campion D
Dartigues JF
Deleuze JF
Lambert JC
Redon R
Ludwig T
Grenier-Boley B
Letort S
Lindenbaum P
Meyer V
Quenez O
Dina C
Bellenguez C
Le Clézio CC
Giemza J
Chatel S
Férec C
Le Marec H
Letenneur L
Nicolas G
Rouault K
Pokaż więcej
Corporate Authors:
French Exome Project Consortium
International Sarcoma Kindred Study
Źródło:
Science (New York, N.Y.) [Science] 2023 Jan 20; Vol. 379 (6629), pp. 253-260. Date of Electronic Publication: 2023 Jan 19.
Typ publikacji:
Journal Article
MeSH Terms:
Genetic Predisposition to Disease*
Mitosis*/genetics
Sarcoma*/genetics
Telomere*/genetics
Germ-Line Mutation*
Humans ; Genetic Variation ; Germ Cells ; Melanoma/genetics ; Shelterin Complex/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy.
Autorzy:
Venizelos A; K.G.Jebsen Center for Genome Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Engebrethsen C; K.G.Jebsen Center for Genome Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Deng W; K.G.Jebsen Center for Genome Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Geisler J; Department of Oncology, Haukeland University Hospital, Bergen, Norway.; Current address: Department of Oncology, Akershus University Hospital, Lørenskog, Norway.
Geisler S; Department of Oncology, Haukeland University Hospital, Bergen, Norway.; Current address: Department of Oncology, Akershus University Hospital, Lørenskog, Norway.
Iversen GT; K.G.Jebsen Center for Genome Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Aas T; Department of Surgery, Haukeland University Hospital, Bergen, Norway.
Aase HS; Department of Radiology, Haukeland University Hospital, Bergen, Norway.
Seyedzadeh M; Department of Radiology, Haukeland University Hospital, Bergen, Norway.; Current address: Department of Radiology, Akershus University Hospital, Lørenskog, Norway.
Steinskog ES; Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Myklebost O; Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Norwegian Cancer Genomics Consortium, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Current address: Department of Clinical Science, University of Bergen, Bergen, Norway.
Nakken S; Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Norwegian Cancer Genomics Consortium, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Vodak D; Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Norwegian Cancer Genomics Consortium, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Hovig E; Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Norwegian Cancer Genomics Consortium, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway.
Meza-Zepeda LA; Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Lønning PE; K.G.Jebsen Center for Genome Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Knappskog S; K.G.Jebsen Center for Genome Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway. .; Department of Oncology, Haukeland University Hospital, Bergen, Norway. .
Eikesdal HP; K.G.Jebsen Center for Genome Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway. .; Department of Oncology, Haukeland University Hospital, Bergen, Norway. .
Pokaż więcej
Źródło:
Genome medicine [Genome Med] 2022 Aug 11; Vol. 14 (1), pp. 86. Date of Electronic Publication: 2022 Aug 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Clonal Evolution ; Cyclophosphamide ; Docetaxel/therapeutic use ; Epirubicin ; Female ; Humans ; Neoadjuvant Therapy ; Taxoids/adverse effects ; Taxoids/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
miR-486-5p expression is regulated by DNA methylation in osteosarcoma.
Autorzy:
Namløs HM; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Skårn M; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Ahmed D; Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Grad I; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Andresen K; Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Kresse SH; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Munthe E; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Serra M; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Scotlandi K; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Llombart-Bosch A; Department of Pathology, Valencia University, Valencia, Spain.
Myklebost O; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department for Clinical Science, University of Bergen, Bergen, Norway.
Lind GE; Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Meza-Zepeda LA; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. Leonardo.Meza-Zepeda@rr-research.no.; Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. Leonardo.Meza-Zepeda@rr-research.no.
Pokaż więcej
Źródło:
BMC genomics [BMC Genomics] 2022 Feb 17; Vol. 23 (1), pp. 142. Date of Electronic Publication: 2022 Feb 17.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Neoplasms*/genetics
Bone Neoplasms*/pathology
MicroRNAs*/genetics
MicroRNAs*/metabolism
Osteosarcoma*/genetics
Osteosarcoma*/pathology
Cell Line, Tumor ; Cell Proliferation ; DNA Methylation ; Epigenesis, Genetic ; Gene Expression Regulation, Neoplastic ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparing the epigenetic landscape in myonuclei purified with a PCM1 antibody from a fast/glycolytic and a slow/oxidative muscle.
Autorzy:
Bengtsen M; Department of Biosciences, University of Oslo, Oslo, Norway.
Winje IM; Department of Biosciences, University of Oslo, Oslo, Norway.
Eftestøl E; Department of Biosciences, University of Oslo, Oslo, Norway.; Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.
Landskron J; Centre for Molecular Medicine Norway, University of Oslo, Oslo, Norway.
Sun C; Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.
Nygård K; Department of Biosciences, University of Oslo, Oslo, Norway.
Domanska D; Department of Pathology, University of Oslo, Oslo, Norway.
Millay DP; Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Meza-Zepeda LA; Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Gundersen K; Department of Biosciences, University of Oslo, Oslo, Norway.
Pokaż więcej
Źródło:
PLoS genetics [PLoS Genet] 2021 Nov 09; Vol. 17 (11), pp. e1009907. Date of Electronic Publication: 2021 Nov 09 (Print Publication: 2021).
Typ publikacji:
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Epigenesis, Genetic*
Autoantigens/*immunology
Cell Cycle Proteins/*immunology
Cell Nucleus/*metabolism
Muscle Fibers, Fast-Twitch/*metabolism
Muscle Fibers, Slow-Twitch/*metabolism
Animals ; Antibodies ; Glycolysis ; Humans ; Mice ; Muscle Cells ; Oxidation-Reduction ; Rats
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The expressed mutational landscape of microsatellite stable colorectal cancers.
Autorzy:
Sveen A; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, P.O. Box 1171 Blindern, NO-0318, Oslo, Norway.
Johannessen B; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.
Eilertsen IA; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, P.O. Box 1171 Blindern, NO-0318, Oslo, Norway.
Røsok BI; K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; Department of Gastrointestinal Surgery, Oslo University Hospital, P.O. Box 4950, NO-0424, Oslo, Norway.
Gulla M; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.
Eide PW; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.
Bruun J; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.
Kryeziu K; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.
Meza-Zepeda LA; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.
Myklebost O; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; Department of Clinical Science, University of Bergen, P.O. Box 7804, NO-5020, Bergen, Norway.
Bjørnbeth BA; K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; Department of Gastrointestinal Surgery, Oslo University Hospital, P.O. Box 4950, NO-0424, Oslo, Norway.
Skotheim RI; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; Department of Informatics, Faculty of Mathematics and Natural Sciences, University of Oslo, P.O. Box 1032 Blindern, NO-0315, Oslo, Norway.
Nesbakken A; K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, P.O. Box 1171 Blindern, NO-0318, Oslo, Norway.; Department of Gastrointestinal Surgery, Oslo University Hospital, P.O. Box 4950, NO-0424, Oslo, Norway.
Lothe RA; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway. .; K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424, Oslo, Norway. .; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, P.O. Box 1171 Blindern, NO-0318, Oslo, Norway. .
Pokaż więcej
Źródło:
Genome medicine [Genome Med] 2021 Sep 01; Vol. 13 (1), pp. 142. Date of Electronic Publication: 2021 Sep 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Microsatellite Repeats*
Mutation*
Colorectal Neoplasms/*genetics
Antineoplastic Agents/therapeutic use ; ErbB Receptors ; GTP Phosphohydrolases ; Humans ; Membrane Proteins ; Proto-Oncogene Proteins c-mdm2 ; Proto-Oncogene Proteins p21(ras) ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism ; Exome Sequencing
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening.
Autorzy:
Grad I; Department of Tumor Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Hanes R; Department of Tumor Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Molecular Cell Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Faculty of Medicine, Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Ayuda-Durán P; Faculty of Medicine, Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Kuijjer ML; Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo, Oslo, Norway.
Enserink JM; Department of Molecular Cell Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Faculty of Medicine, Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Faculty of Mathematics and Natural Sciences, Department of Biosciences, University of Oslo, Oslo, Norway.
Meza-Zepeda LA; Department of Tumor Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Core Facilities, Genomics Core Facility, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway.
Myklebost O; Department of Tumor Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2021 Mar 10; Vol. 16 (3), pp. e0248140. Date of Electronic Publication: 2021 Mar 10 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Evaluation, Preclinical/*methods
High-Throughput Screening Assays/*methods
Liposarcoma/*drug therapy
Acrylamides/pharmacology ; Antineoplastic Agents/analysis ; Antineoplastic Agents/chemistry ; Biomarkers, Pharmacological ; Boron Compounds/pharmacology ; Cell Line, Tumor ; Diterpenes/pharmacology ; Epoxy Compounds/pharmacology ; Glycine/analogs & derivatives ; Glycine/pharmacology ; Humans ; Hydroxamic Acids/pharmacology ; Imidazoles/pharmacology ; Naphthoquinones/pharmacology ; Phenanthrenes/pharmacology ; Piperidines/pharmacology ; Pyridazines/pharmacology ; Quinolines/pharmacology ; Small Molecule Libraries/pharmacology ; Sulfonamides/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Accurate 3-gene-signature for early diagnosis of liposarcoma progression.
Autorzy:
Serguienko A; 1Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Norwegian Radium Hospital, Ullernchausséen 70, 0379 Oslo, Norway.
Braadland P; 1Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Norwegian Radium Hospital, Ullernchausséen 70, 0379 Oslo, Norway.
Meza-Zepeda LA; 1Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Norwegian Radium Hospital, Ullernchausséen 70, 0379 Oslo, Norway.; 2Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Norwegian Radium Hospital, Ullernchausséen 70, 0379 Oslo, Norway.; 3Department of Clinical Science, University of Bergen and Haukeland University Hospital, 5020 Bergen, Norway.
Bjerkehagen B; 4Department of Pathology, Oslo University Hospital, Ullernchausséen 64, 0379 Oslo, Norway.; 5Institute of Oral Biology, University of Oslo, Oslo, Norway.; 6Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Myklebost O; 1Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Norwegian Radium Hospital, Ullernchausséen 70, 0379 Oslo, Norway.; 3Department of Clinical Science, University of Bergen and Haukeland University Hospital, 5020 Bergen, Norway.
Pokaż więcej
Źródło:
Clinical sarcoma research [Clin Sarcoma Res] 2020 Mar 05; Vol. 10, pp. 4. Date of Electronic Publication: 2020 Mar 05 (Print Publication: 2020).
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.
Autorzy:
Forthun RB; Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.
Hovland R; Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway.; Department of Biosciences, University of Bergen, Bergen, Norway.
Schuster C; Centre of Cancer Biomarkers, CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Puntervoll H; Centre of Cancer Biomarkers, CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
Brodal HP; Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.
Namløs HM; Department of Tumour Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Aasheim LB; Norwegian Cancer Genomics Consortium, Institute for Cancer Research, The Norwegian Radium Hospital/Oslo University Hospital, Oslo, Norway.
Meza-Zepeda LA; Department of Tumour Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Norwegian Cancer Genomics Consortium, Institute for Cancer Research, The Norwegian Radium Hospital/Oslo University Hospital, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Oslo University Hospital, Oslo, Norway.
Gjertsen BT; Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.; Centre of Cancer Biomarkers, CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
Knappskog S; Department of Oncology, Haukeland University Hospital, Bergen, Norway.; K.G. Jebsen Center for Genome Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.
Straume O; Centre of Cancer Biomarkers, CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway. .; Department of Oncology, Haukeland University Hospital, Bergen, Norway. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Nov 25; Vol. 9 (1), pp. 17471. Date of Electronic Publication: 2019 Nov 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents, Immunological/*therapeutic use
Bevacizumab/*therapeutic use
Circulating Tumor DNA/*analysis
High-Throughput Nucleotide Sequencing/*methods
Melanoma/*drug therapy
Adult ; Aged ; Antineoplastic Agents, Immunological/pharmacology ; Bevacizumab/pharmacology ; Female ; GTP Phosphohydrolases/genetics ; Humans ; L-Lactate Dehydrogenase (Cytochrome)/genetics ; Male ; Melanoma/genetics ; Membrane Proteins/genetics ; Middle Aged ; Mutation ; Neoplasm Metastasis ; Prognosis ; Proto-Oncogene Proteins B-raf/genetics ; Survival Analysis ; Telomerase/genetics ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.
Autorzy:
Hanes R; Department of Tumor Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway. .; Norwegian Cancer Genomics Consortium, 0379 Oslo, Norway. .
Munthe E; Department of Tumor Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway. .
Grad I; Department of Tumor Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway. .
Han J; Centre for Cancer Biomarkers (CCBIO), Department of Clinical Sciences, University of Bergen, 5021 Bergen, Norway. .
Karlsen I; Centre for Cancer Biomarkers (CCBIO), Department of Clinical Sciences, University of Bergen, 5021 Bergen, Norway. .; KinN Therapeutics AS, 5021 Bergen, Norway. .
McCormack E; Centre for Cancer Biomarkers (CCBIO), Department of Clinical Sciences, University of Bergen, 5021 Bergen, Norway. .; Department of Internal Medicine, Hematology Section, Haukeland University Hospital, 5021 Bergen, Norway. .
Meza-Zepeda LA; Department of Tumor Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway. Leonardo.A.Meza-Zepeda@rr-research.no.; Norwegian Cancer Genomics Consortium, 0379 Oslo, Norway. Leonardo.A.Meza-Zepeda@rr-research.no.; Genomics Core Facility, Department of Core Facilities, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway. Leonardo.A.Meza-Zepeda@rr-research.no.
Stratford EW; Department of Tumor Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway. .
Myklebost O; Department of Tumor Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway. .; Norwegian Cancer Genomics Consortium, 0379 Oslo, Norway. .; Department of Clinical Science, University of Bergen, 5020 Bergen, Norway. .
Pokaż więcej
Źródło:
Cells [Cells] 2019 Feb 21; Vol. 8 (2). Date of Electronic Publication: 2019 Feb 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Evaluation, Preclinical*
Gene Amplification*
Adaptor Proteins, Signal Transducing/*genetics
Indazoles/*therapeutic use
Liposarcoma/*drug therapy
Liposarcoma/*genetics
Membrane Proteins/*genetics
Receptor, Fibroblast Growth Factor, Type 2/*antagonists & inhibitors
Animals ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Humans ; Indazoles/pharmacology ; MAP Kinase Signaling System/drug effects ; Mice ; Phenylurea Compounds/pharmacology ; Phenylurea Compounds/therapeutic use ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use ; Receptor, Fibroblast Growth Factor, Type 2/metabolism ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples.
Autorzy:
Kresse SH; Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Namløs HM; Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Lorenz S; Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Berner JM; Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Myklebost O; Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway.; Norwegian Cancer Genomics Consortium (cancergenomics.no), Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Bjerkehagen B; Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Meza-Zepeda LA; Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Norwegian Cancer Genomics Consortium (cancergenomics.no), Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2018 May 17; Vol. 13 (5), pp. e0197456. Date of Electronic Publication: 2018 May 17 (Print Publication: 2018).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Paraffin Embedding*
DNA/*isolation & purification
High-Throughput Nucleotide Sequencing/*methods
RNA/*isolation & purification
Animals ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 51

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies